Imperial College London Centenary
About Imperial
About ImperialContacts/getting hereAlumniResearchCoursesAbout this site
Select your text size  for this site here: Small Text Normal Text Large Text Extra Large Text

Note: Some of the graphical elements of this site are only visible to browsers that support accepted web standards. The content of this site is, however, accessible to any browser or Internet device.


Meningitis clotting pathway cracked by UK and US scientists

Strictly embargoed for release
22:00 BST / 17:00 EST Wednesday 8 August 2001

Researchers in the UK and US report in the New England Journal of Medicine this week (9 August) the results of a study in children which may explain why patients with meningococcal septicaemia develop widespread clotting within blood vessels leading to death or loss of limb and digits.

The team from Imperial College and St Mary's Hospital, London, in collaboration with research groups at the University of Bristol, UK, and Oklahoma, USA, say that their work offers new directions for treatment of the blood poisoning form of meningitis.

In healthy individuals, a number of proteins are present in the blood which act to prevent clots forming in veins and arteries. One of these is a recently identified protein called Protein C, which when activated is a powerful inhibitor of clot formation.

The NEJM study of 21 children establishes for the first time that patients suffering from meningococcal septicaemia have lost two key proteins (thrombomodulin and endothelial Protein C receptor) required to activate Protein C on the lining of blood vessels.

This serious defect leads to an inability to control clotting within arteries and veins and opens the way to widespread clot formation, a hallmark of meningococcal septicaemia, often visible as rashes on the skin.

To date the development of effective treatments to prevent or reverse this clot formation has been hampered by a lack of understanding of the mechanisms involved.

Leader of the study Professor Michael Levin of Imperial College said:

"Our study has identified a key mechanism involved in the devastating complications of meningococcal disease, and offers new insights into how the disease might best be treated.

"A defect in the activation of Protein C could, theoretically, be treated by administration of Protein C in its active form, thus by-passing the requirements for activation on the surfaces of blood vessels."

Clinical trials are currently underway to assess the safety and feasibility of this treatment.

Denise Vaughan, Chief Executive of funders Meningitis Research Foundation said:

"We are delighted with the outcome of this research which has the potential to prevent death and disability from meningitis and septicaemia."

The authors of the paper are Dr Saul Faust, Professor Michael Levin, Odile Harrison, Dr Robert Goldin and Dr Sheila Kondaveeti (Imperial College and St Mary's Hospital, UK); Marion Lockhart (Oklahoma Medical Research Foundation, USA); Dr Zoltan Lasik and Dr Charles Esmon (University of Oklahoma Health Sciences Center, USA); and Dr Robert Heyderman (University of Bristol, UK).

The programme of research has been supported by a grant from the Meningitis Research Foundation grant in excess of UKP700,000, with additional support via a training fellowship from the Medical Research Council.

For more information please contact:

Dr Saul Faust
Department of Paediatrics
Faculty of Medicine, Imperial College
Tel: +44 20 7886 6377

Tom Miller
Imperial College Press Office
Tel: +44 20 7594 6704
Mobile: +44 7803 886248

Julia Warren
Meningitis Research Foundation
Tel: +44 1454 281811
Mob: +44 7711 057875

Notes to Editors

1. Imperial College of Science, Technology and Medicine is the largest applied science, technology and medicine university institution in the UK. It is consistently rated in the top three UKated in the top three UK university institutions for research quality, with one of the largest annual turnovers (UKP339 million in 1999-2000) and research incomes (UKP176 million in 1999-2000). Web site: